脓毒症患者病前使用血管紧张素转换酶抑制剂或血管紧张素II受体拮抗剂的影响
本研究为系统评价与Meta分析,检索Embase、Cochrane Central Register of Controlled Trials和MEDLINE,纳入15项研究(N=96,159),评估脓毒症患者病前使用ACEI/ARB对短期死亡率(≤30天、住院或ICU死亡率)和急性肾损伤(AKI)的影响。结果显示,未校正短期死亡率OR为0.86(95%CI 0.67-1.11;P=0.24;I²=88%),校正后OR为0.74(95%CI 0.59-0.93;P<0.01;I²=93%);AKI的校正OR为1.57(95%CI 1.26-1.96;P<0.01;I²=69%)。结论认为,病前使用ACEI/ARB与脓毒症患者短期死亡率显著降低相关,但AKI风险显著升高。
要点
- 在脓毒症患者中,病前使用ACEI/ARB与短期死亡率校正OR 0.74(95%CI 0.59-0.93;P<0.01;I²=93%)显著降低相关。
- 未校正分析中,病前使用ACEI/ARB与短期死亡率OR 0.86(95%CI 0.67-1.11;P=0.24;I²=88%)无显著关联。
- 病前使用ACEI/ARB与急性肾损伤风险校正OR 1.57(95%CI 1.26-1.96;P<0.01;I²=69%)显著升高相关。
- 共纳入15项研究(N=96,159),其中11项(N=40,360)报告未校正短期死亡率,5项报告校正OR,7项报告AKI的校正OR。
- 分析采用随机效应模型,主要结局为短期死亡率(≤30天、住院或ICU死亡率),次要结局为AKI。
适用人群与场景
- 年龄≥16岁的脓毒症患者,病前使用ACEI/ARB或未使用。
- 纳入随机对照试验、队列研究和横断面研究。
研究设计与关键结果
- 研究类型:系统评价与Meta分析,检索Embase、Cochrane Central Register of Controlled Trials和MEDLINE,方案注册于PROSPERO(CRD42022309129),共纳入15项研究(N=96,159)。
- 主要结局:短期死亡率(≤30天、住院或ICU死亡率)。11项研究(N=40,360)报告未校正短期死亡率,合并OR 0.86(95%CI 0.67-1.11;P=0.24;I²=88%);5项研究报告校正OR 0.74(95%CI 0.59-0.93;P<0.01;I²=93%)。
- 次要结局:急性肾损伤(AKI)。7项研究报告病前使用ACEI/ARB的AKI校正OR 1.57(95%CI 1.26-1.96;P<0.01;I²=69%)。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,病前使用ACEI/ARB与脓毒症患者短期死亡率显著降低相关,尽管AKI风险显著升高。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: The aim of this study was to conduct a systematic review and meta-analysis to investigate the effect of the premorbid use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (ACEI/ARB) on short-term mortality in patients with sepsis.
DATA SOURCES: Embase, the Cochrane Central Register of Controlled Trials, and MEDLINE were searched for studies based on the below eligibility criteria. The protocol was registered at the PROSPERO (CRD42022309129).
STUDY SELECTION: Eligibility criteria were as follows: (1) randomized controlled trials, cohort studies, cross-sectional studies, (2) patients with sepsis aged ≥16 years, and (3) received premorbid ACEI/ARB, or not.
DATA EXTRACTION: The patient and study characteristics and outcomes were extracted. All analyses were presented with the use of random-effects models. The primary outcome was short-term mortality defined as ≤30-day, in-hospital, or intensive care unit (ICU)- mortality. The secondary outcome was acute kidney injury (AKI).
DATA SYNTHESIS: Fifteen studies (N = 96,159) met the eligibility criteria. Of these, eleven studies (N = 40,360) reported unadjusted short-term mortalities. The pooled odds ratio (OR) of short-term mortality with the premorbid use of ACEI/ARB was as follows: OR, 0.86; 95% confidence interval (CI), 0.67 to 1.11; P = 0.24, I2 = 88%. Five studies reported an adjusted OR of short-term mortality with the premorbid use of ACEI/ARB as follows: OR, 0.74; 95%CI, 0.59 to 0.93; P < 0.01, I2 = 93%. Seven studies reported the pooled adjusted OR of AKI with the premorbid use of ACEI/ARB as follows: OR: 1.57, 95%CI: 1.26-1.96, p < 0.01, I2 = 69%.
CONCLUSION: In this meta-analysis, the premorbid ACEI/ARB was associated with significantly lower short-term mortality in patients with sepsis despite the significantly higher risk of AKI.
参考来源
- Hasegawa D, Lee YI, Prasitlumkum N, et al. Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis. Am J Emerg Med. 2022. PMID: 36270096. doi:10.1016/j.ajem.2022.10.006
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。